Lowering compensation to research subjects to protect them from “undue inducement” is a misguided attempt to shoehorn a concern about exploitation into the framework of autonomy. We suggest that oversight bodies should be less concerned about undue influence than about exploitation of subjects. Avoiding exploitation in human subjects research requires not only increasing compensation, but enhancing the dignity of research participation.
Get full access to this article
View all access options for this article.
References
1.
Coyle and Sharpe, “Maniacs in a Living Hell,”The Insane (But Hilarious) Minds of Coyle & Sharpe, available at <https://www.youtube.com/watch?v=_GG9zSr9CkY> (last visited August 29, 2017).
2.
See, e.g., Office for Human Research Protections, Protecting Human Research Subjects: Institutional Review Board Guidebook (Washington D.C.: U.S. Government Printing Office, 1993): at Chapter 3, Section B, 33.
3.
E. W.St. Clair, “The Calm After the Cytokine Storm: Lessons From the TGN1412 Trial,”Journal of Clinical Investigation118, no. 4 (2008): 1344–1347.
4.
L.Almeida, B.Azevedo, T.Nunes, M.Vaz-da-Silva, and P.Soares-da-Silva, “Why Healthy Subjects Volunteer for Phase I Studies and How They Perceive Their Participation,”European Journal of Clinical Pharmacology63, 11 (2007):1085–1094; T. Monahan and J. Fisher, “I'm Still a Hustler’: Entrepreneurial Responses to Precarity by Participants in Phase I Clinical Trials,” Economy and Society 44, no. 4 (2015): 545-566.
5.
R.Abadie, The Professional Guinea Pig (Durham, N.C.: Duke University Press, 2010): at 54-57; C. Elliott, “Guinea-Pigging,” The New Yorker, January 7, 2008, 36-41; M. Cottingham and J. Fisher, “Risk and Emotion Among Healthy Volunteers in Clinical Trials,” Social Psychology Quarterly 79, no. 3 (2016): 222-242.
6.
See, e.g., R.Nelson, T.Beauchamp, V.Miller, W.Reynolds, R.Ittenbach, and M.Luce, “The Concept of Voluntary Consent,”American Journal of Bioethics11, no. 8 (2011): 6-16, at 9 (“The federal regulations governing research in the United States require investigators to ‘minimize the possibility of’ undue inducement, but they do not define, analyze, or explain this notion…”).
7.
H.Lynch, “Protecting Human Research Subjects as Human Research Workers,” in I. GlennCohen and Holly FernandezLynch, eds., Human Subjects Research Regulation: Perspectives on the Future (Cambridge: MIT Press, 2014): Chapter 21, at 332 (“The bigger problem for research subjects is that the regulatory system in some ways encourages their exploitation by effectively precluding high payments.”).
8.
See, e.g., D. B.Resnik, “Research Participation and Financial Inducements,”American Journal of Bioethics11, no. 2 (2001): 54-56, at 55.
9.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report (Washington, D.C.: Government Printing Office, 1979): at 8.
10.
Id.
11.
R.Faden and T.Beauchamp, “Coercion, Manipulation, and Persuasion,” in A History and Theory of Informed Consent (New York: Oxford University Press, 1986): Chapter 10, at 337-381.
12.
Id. at 358-360.
13.
Id. at 358.
14.
See, e.g., Council of International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO), International Ethical Guidelines for Biomedical Research involving Human Subjects, Geneva, 2002: 46; Department of Health and Human Services (DHHS), “Protection of Human Subjects of Research (‘The Common Rule’)” 45 C.F.R. § 46.116; Food and Drug Administration, Department of Health and Human Services (DHHS), “Payment to Research Subjects – Information Sheet,” available at <http://www.fda.gov/RegulatoryInformation/Guidances/ucm126429.htm> (last visited May 2, 2017).
15.
Faden and Beauchamp, supra note 11, at 360.
16.
E.Largent, C.Grady, F.Miller and A.Wertheimer, “Misconceptions About Coercion and Undue Influence,”Bioethics27, no. 9 (2013): 500-507.
17.
For example, see P.Appelbaum, C.Lidz, and R.Klitzman, “Voluntariness of Consent to Research: A Conceptual Model,”Hastings Center Report39, no. 1 (2009): 30-39; R. Nelson and J. Merz, “Voluntariness of Consent for Research: An Empirical and Conceptual Review,” Medical Care 40, no. 9 Supplement (2002): V-69-V-80; Nelson et al., supra note 6.
18.
M. Cottingham and J. Fisher, supra note 6.
19.
World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, 2000, Article 17 (“[m]edical research involving a disadvantaged or vulnerable population or community is only justified if…there is a reasonable likelihood that this population or community stands to benefit from the results of the research.”). See also Belmont Report, supra note 9, at 6; 45 C.F.R. § 46.111(3); E. Emanuel, D. Wendler, and C. Grady, “What Makes Clinical Research Ethical?,” JAMA 283, no. 20 (2000): 2701-2711, at 2704-2705.
20.
See, e.g., T.Lemmens and C.Elliott, “Guinea Pigs on the Payroll: The Ethics of Paying Research Subjects,”Accountability in Research: Policies and Quality Assurance7, no. 1 (1999): 3-20, at 13; J. Fisher, Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials (New Brunswick, N.J.: Rutgers University Press, 2009) at 151-152; A. Iltis, “Payments to Normal Healthy Volunteers in Phase 1 Trials: Avoiding Undue Influence While Distributing Fairly the Burdens of Research Participation,” Journal of Medicine and Philosophy 34, no. 1 (2009): 68-90, at 72.
21.
Fisher, supra note 20, at 130. See also L.Stunkel, M.Benson, L.McLellan, N.Sinaii, G.Bedarida, E.Emanuel, and C.Grady, “Comprehension and Informed Consent: Assessing the Effect of a Short Consent Form,”IRB: Ethics & Human Research32, no. 4 (2010): 1-9, at 6; Iltis, supra note 20, at 72; M. Cottingham and J. Fisher, supra note 6; J. Fisher and C. Kalbaugh, “Challenging Assumptions About Minority Participation in U.S. Clinical Research,” American Journal of Public Health 101, no. 12 (2011): 2217-2222.
22.
For example, see C.Elliott, The Best-Selling, Billion-Dollar Pills Tested on Homeless People, Medium (2014), available at <https://medium.com/matter/did-big-pharma-test-your-meds-on-homeless-people-a6d8d3fc7dfe> (last visited May 2, 2017); D. Evans, M. Smith, and L. Willen, “Big Pharma's Shameful Secret,” Bloomberg Markets, December 2005, at 36-62; L. Cohen, “Lilly's ‘Quick Cash’ to Habitués of Shelters Vanishes Quickly,” Wall Street Journal, November 14, 1996, at A1.
23.
C.Elliott and R.Abadie, “Exploiting a Research Underclass in Phase 1 Clinical Trials,”New England Journal of Medicine358, no. 22 (2008): 2316-2317.
24.
Nelson et al., supra note 6, at 9.
25.
Institutional Review Board Guidebook, supra note 2, at 33.
26.
Id. at 34.
27.
Largent et al., supra note 16, at 500.
28.
N.Dickert, E.Emanuel, and C.Grady, “Paying Research Subjects: An Analysis of Current Policies,”Annals of Internal Medicine136, no. 5 (2002): 368-373, 372.
29.
E.Largent, C.Grady, F.Miller, and A.Wertheimer, “Money, Coercion, and Undue Inducement: A Survey of Attitudes About Payments to Research Subjects,”IRB34, no. 1 (2012): 1-8.
30.
Id.
31.
See Lynch, supra note 7; Lemmens and Elliott, supra note 20, at 13-14.
32.
H.Lynch, “Human Research Subjects as Human Research Workers,”Yale Journal of Health Policy, Law & Ethics14 (2014): 123-193, 157 (“[F]ear of undue inducement plays no role whatsoever in the legal regulation of wages paid to workers. In fact, worklaw imposes no ceiling – explicit or implicit – on how much workers may be paid…”).
33.
Johnson v. International Business Machines Corp., 891 F. Supp. 522, 531 (N.D. Cal. 1995).
34.
“The fairness of the resulting exchange is often a critical factor in cases involving threats.” American Law Institute, Restatement (Second) of Contracts (1979), at § 176, comment a. Courts are also more likely to invalidate a contract because of a party's incapacity when the terms of the agreement appear unfair to the impaired party. Id. at § 15(2).
35.
Id. at § 208 and § 208 comment c. Although inadequate consideration is not sufficient on its own to invalidate a contract, “gross disparity in the values exchanged may be an important factor in a determination that a contract is unconscionable.” Id. at § 208 comment c. See also Eric A. Posner, “Contract Law in the Welfare State: A Defense of the Unconscionability Doctrine, Usury Laws, and Related Limitations on the Freedom to Contract,” Journal of Legal Studies 24, no. 2 (1995): 283-319, at 304 (noting that the doctrine of substantive unconscionability “condemns contracts involving substantial disparities between the contract price and the market price” and that the doctrine “dovetail[s] with the conventional view that courts should strike down involuntary contracts (as… price disparity is strong evidence of bargaining abuse)”).
36.
Lynch notes some interesting historical examples of laws that have limited wages — including, for example, some “passed by some state legislatures in the South after emancipation for reasons that were decidedly anti-worker.” As Lynch notes, “[i] n none of these examples, however, is payment limited out of fear that workers will suffer from undue inducement.” Lynch, supra note 32, at 160.
37.
Faden and Beauchamp, supra note 11, at 360.
38.
Steinman v. Malamed, 185 Cal.App.4th 1550, 1559 (2010). A.Wertheimer, Coercion (Princeton, N.J.: Princeton University Press, 1990): at 41 (noting that in contract law “there is generally no duress if A's proposal is not wrongful – even if it serves to create B's dilemma.”).
39.
Johnson, supra note 33, at 529.
40.
Restatement (Second) of Contracts, supra note 34, at § 176 comment a (in considering whether a contract should be invalidated on the basis of duress or undue influence, “the fairness of the resulting exchange is often a critical factor.”).
41.
Resnik, supra note 8, at 55.
42.
198 U.S. 45 (1905).
43.
Adkins v. Children's Hospital, 261 U.S. 525 (1923); Hammer v. Dagenhart, 247 U.S. 251 (1918); Adair v. United States, 208 U.S. 161 (1908).
44.
A.Wertheimer, “Exploitation in Clinical Research,” in E.Emanuel, C.Grady, R.Crouch, R.Lie, F.Miller, and D.Wendler, eds., The Oxford Textbook of Clinical Research Ethics (New York: Oxford University Press, 2008): at 202.
45.
J. H.Jones, “The Tuskegee Syphilis Experiment,” in The Oxford Textbook of Clinical Research Ethics, supra note 44, at 90.
46.
Wertheimer, supra note 44, at 203.
47.
Cottingham and Fisher, supra note 6.
48.
A.Werthheimer, Rethinking the Ethics of Clinical Research (New York: Oxford University Press, 2011), at 201.
49.
Office of the Legislative Auditor, State of Minnesota, A Clinical Drug Study at the University of Minnesota Department of Psychiatry: The Dan Markingson Case (2015) [hereinafter Legislative Auditor Report], available at <www.auditor.leg.state.mn.us/sreview/Markingson.pdf> (last visited August 29, 2017).
50.
Wertheimer, supra note 44, at 205.
51.
E.Emanuel, “Undue Inducement: Nonsense on Stilts?,”American Journal of Bioethics5, no. 5 (2005): 9-13.
The Lewin Group, Task Order Proposal No. 2, “Care/Compensation for Injuries in Clinical Research,” Draft of the final report prepared for the Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, Falls Church, VA: The Lewin Group, May 18, 2005. (Contract no. HHS 100-03-0005). See also C. Elliott, “Justice for Injured Research Subjects,” New England Journal of Medicine 367, no. 1 (2012): 6-8.
55.
D. B.Resnik, E.Parasidis, K.Carroll, J.M.Evans, E. R.Pike, and G. E.Kissling, “Research-Related Injury Compensation Policies of U.S. Research Institutions,”IRB36, no. 1 (2014): 12-19.
56.
Id.
57.
L.Tamariz, A.Palacio, M.Robert, and E. N.Marcus, “Improving the Informed Consent Process for Research Subjects with Low Literacy: A Systematic Review,”Journal of General Internal Medicine28, no. 1 (2006): 121-126.
58.
J.Fisher, “Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials,”Science, Technology, & Human Values40, no. 2 (2015): 199-226.
59.
C. A.van den Bogert, P. C.Souverein, C. T. M.Brekelmans, S. W. J.Janssen, G. H.Koëter, H. G. M.Leufkens, and L. M.Bouter, “Non-Publication Is Common Among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials,”PLOS One11, no. 1 (2006); Public Health Service Act, 42 U.S.C. § 282 (j) (2007).
60.
Declaration of Helsinki, supra note 19, at 35.
61.
Office of Inspector General, Department of Health and Human Services, The Food and Drug Administration's Oversight of Clinical Trials, September2007, available at <https://oig.hhs.gov/oei/reports/oei-01-06-00160.pdf> (last visited August 29, 2017).
62.
E. J.Emanuel, G.Bedarida, K.Macci, N. B.Gabler, A.Rid, D.Wendler, “Quantifying the Risks of Non-Oncology Phase I Research in Healthy Volunteers: Meta-Analysis of Phase I Studies,”BMJ350 (2015): 1-9.
63.
E.Emanuel, “Ending Concerns about Undue Inducement,”Journal of Law, Medicine, & Ethics32, no. 1 (2004): 100-105, at 104.
64.
R. F.Wilson, “The Death of Jesse Gelsinger: New Evidence of the Influence of Money and Prestige in Human Research,”American Journal of Law & Medicine36, 2-3 (2010): 295-325; H. Edgar and D. J. Rothman, “The Institutional Review Board and Beyond: Future Challenges to the Ethics of Human Experimentation,” Milbank Quarterly 73, no. 4 (1995): 489-506, at 493; D. Wilson and D. Heath, “Patients Never Knew the Full Danger of Trials They Staked Their Lives On,” Seattle Times, March 11, 2001, at A1; A. Michaud, “UC Drops Controversial Psychoses Tests: Critics Contend Studies Unethical,” Cincinnati Enquirer, May 6, 1999, at 1; A. Malhotra, D. A. Pinals, C. M. Adler, I. Elman, A. Clifton, D. Pickar, and A. Breier, “Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics,” Neuropsychopharmacology 17, no. 3 (1997): 141-150; S. M. Southwick, J. H. Krystal, J. D. Bremner, C.A. Morgan, A.L. Nicolaou, L.M. Nagy, D.R. Johnson, G.R. Heninger, D.S. Charney, “Noradrenergic and Serotonergic Function in Post Traumatic Stress Disorder,” Archives of General Psychiatry 54, no. 8 (1997): 749-758; Legislative Auditor Report, supra note 49, at 14; J. Baillon, “U of M Drug Study Criticism Grows,” KMSP TV, May 19, 2014, available at <www.fox9.com/health/1647039-story> (last visited August 29, 2017); C. Elliott, “U Owes Mistreated Psychiatric Subjects an Apology,” Minneapolis Star Tribune, October 7, 2015, available at <http://www.startribune.com/u-owes-mis-treated-psychiatric-subjects-an-apology/331165371/> (last visited August 29, 2017); C. Elliott, “Why Research Oversight Bodies Should Interview Research Subjects,” IRB: Ethics and Human Research 39, no. 2 (2017), 8-13.
65.
Legislative Auditor Report, supra note 49, at 20; M.Lamkin and C.Elliott, “Involuntarily Committed Patients as Prisoners,”Richmond Law Review51, no. 101 (2017): 114-115.
66.
E.Rosenthal, “New York Seeks to Tighten Rules on Medical Research,”New York Times, September27, 1996, at B4; E. Rosenthal, “British Rethinking Rules After Ill-Fated Drug Trial,” New York Times, April 8, 2006, at A1; G. Kolata, “Johns Hopkins Admits Fault in Fatal Experiment,” New York Times, July 17, 2001, at A16; J. K. Wall and J. Tuohy, “Suicide Brings Changes to Lilly Drug Trials,” Indianapolis Star, February 11, 2004, at A1; C. Elliott, supra note 22; K. Messmer and J. Blasingim, “An Analysis of Specific Phase I Safety Issues,” Regulatory Rapporteur 14, no. 2 (2017): 23-27.
67.
See O. K.Obasogie, “Prisoners as Human Subjects: A Closer Look at the Institute of Medicine's Recommendations to Loosen Current Restrictions on Using Prisoners in Scientific Research,”Stanford Journal of Civil Rights and Civil Liberties6, no. 41 (2010): 75–77; Evans et al., supra note 22, at 39; T. Lemmens and P. Miller, “The Human Subjects Trade: Ethical and Legal Issues Surrounding Recruitment Incentives,” Journal of Law, Medicine & Ethics 31, no. 3 (2003): 398-419.
68.
R. J.Sample, Exploitation: What It Is and Why It's Wrong (Oxford: Rowman & Littlefield Publishers, 2003): at 57.
69.
J.Wortham, “Use of Homeless as Internet Hot Spots Back-fires on Marketer,”New York Times, March12, 2012, at B1.
70.
C.Overall, “What's Wrong With Prostitution? Evaluating Sex Work,”Signs: Journal of Women in Culture and Society17, no. 4 (1992): 705-724.
71.
T.Wolfe, The Right Stuff (New York: Farrar, Straus and Giroux, 1979): at 100, 148.
72.
R.Abadie, The Professional Guinea Pig: Big Pharma and the Risky World of Human Research Subjects (Durham, N.C.: Duke University Press, 2005): at 7-8, 48, 162; M. Murrmann, “I Was a Teenage Guinea Pig!” Washington City Paper, November 22, 1996, available at <http://www.washingtoncitypaper.com/news/article/13011942/i-was-a-teenage-guinea-pig> (last visited August 29, 2017).
73.
R.Helms, ed. Guinea Pig Zero: An Anthology for the Journal of Human Research Subjects (New Orleans, LA: Garrett County Press, 2005): at 207, 200.
E.Pike, “Recovering From Research: A No-Fault Proposal to Compensate Injured Research Participants,”American Journal of Law, Medicine & Ethics38, no. 1 (2012): 7-62.
